Johnson/NNP &/CC Johnson/NNP reported/VBD a/DT 10/CD %/NN rise/NN in/IN third-quarter/JJ net/JJ income/NN on/IN a/DT 12/CD %/NN sales/NNS increase/NN -/: results/NNS that/WDT *T*-2/-NONE- were/VBD driven/VBN *-1/-NONE- particularly/RB by/IN new/JJ products/NNS including/VBG pharmaceuticals/NNS and/CC the/DT company/NN 's/POS professional/JJ operations/NNS ./.
Net/NN for/IN the/DT New/NNP Brunswick/NNP ,/, N.J./NNP ,/, maker/NN of/IN health-care/NN products/NNS climbed/VBD to/TO $/$ 265/CD million/CD *U*/-NONE- ,/, or/CC 80/CD cents/NNS a/DT share/NN ,/, from/IN $/$ 240/CD million/CD *U*/-NONE- ,/, or/CC 71/CD cents/NNS a/DT share/NN ,/, in/IN the/DT year-earlier/JJ period/NN ./.
Sales/NNS rose/VBD to/TO $/$ 2.45/CD billion/CD *U*/-NONE- from/IN $/$ 2.2/CD billion/CD *U*/-NONE- ./.
The/DT year-ago/JJ per-share/JJ earnings/NNS are/VBP adjusted/VBN *-1/-NONE- to/TO reflect/VB a/DT 2-for-1/JJ stock/NN split/VBD last/JJ May/NNP ./.
In/IN a/DT statement/NN ,/, Ralph/NNP S./NNP Larsen/NNP ,/, chairman/NN and/CC chief/JJ executive/JJ officer/NN ,/, said/VBD 0/-NONE- the/DT company/NN was/VBD pleased/JJ with/IN its/PRP$ third-quarter/JJ sales/NNS performance/NN ,/, ``/`` especially/RB in/IN light/NN of/IN the/DT extremely/RB competitive/JJ environment/NN in/IN domestic/JJ consumer/NN markets/NNS and/CC the/DT negative/JJ impact/NN of/IN unfavorable/JJ exchange/NN rates/NNS this/DT quarter/NN ./. ''/''
David/NNP J./NNP Lothson/NNP ,/, an/DT industry/NN analyst/NN for/IN PaineWebber/NNP Group/NNP Inc./NNP ,/, said/VBD 0/-NONE- Johnson/NNP &/CC Johnson/NNP 's/POS results/NNS slightly/RB exceeded/VBD his/PRP$ expectations/NNS for/IN the/DT third/JJ quarter/NN ./.
In/IN New/NNP York/NNP Stock/NNP Exchange/NNP composite/NN trading/VBG yesterday/NN ,/, Johnson/NNP &/CC Johnson/NNP shares/NNS fell/VBD 37.5/CD cents/NNS to/TO $/$ 54.625/CD *U*/-NONE- ./.
Mr./NNP Larsen/NNP noted/VBD ``/`` substantial/JJ sales/NNS growth/NN ''/'' for/IN the/DT recently/RB introduced/VBN Acuvue/NNP disposable/JJ contact/NN lens/NN and/CC Hismanal/NNP ,/, a/DT once-a-day/JJ antihistamine/NN ./.
Eprex/NNP ,/, used/VBN */-NONE- by/IN dialysis/NN patients/NNS who/WP *T*-1/-NONE- are/VBP anemic/JJ ,/, and/CC Prepulsid/NN ,/, a/DT gastro-intestinal/JJ drug/NN ,/, did/VBD well/RB overseas/RB ,/, he/PRP said/VBD 0/-NONE- *T*-2/-NONE- ./.
Despite/IN health-care/NN cost/NN controls/NNS and/CC programs/NNS 0/-NONE- *T*-2/-NONE- to/TO hold/VB down/RP inventory/NN ,/, the/DT professional/JJ division/NN ,/, which/WDT *T*-1/-NONE- makes/VBZ products/NNS including/VBG sutures/NNS and/CC surgical/JJ stapling/NN equipment/NN ,/, ``/`` achieved/VBD solid/JJ growth/NN ,/, ''/'' Johnson/NNP &/CC Johnson/NNP said/VBD 0/-NONE- *T*-3/-NONE- ./.
But/CC domestic/JJ consumer/NN sales/NNS slipped/VBD 1.2/CD %/NN for/IN the/DT quarter/NN ,/, to/TO $/$ 490/CD million/CD *U*/-NONE- from/IN $/$ 496/CD million/CD *U*/-NONE- ./.
The/DT company/NN cited/VBD softness/NN in/IN the/DT retail/JJ health/NN and/CC beauty/NN aids/NNS category/NN ,/, ``/`` as/RB well/RB as/IN the/DT intense/JJ competition/NN in/IN the/DT company/NN 's/POS sanitary/JJ protection/NN product/NN line/NN ./. ''/''
Overseas/JJ sales/NNS were/VBD stronger/JJR ,/, principally/RB because/IN of/IN a/DT rebound/NN in/IN Brazil/NNP ,/, where/WRB economic/JJ turmoil/NN had/VBD hurt/VBN year-earlier/JJ results/NNS *T*-1/-NONE- ,/, Johnson/NNP &/CC Johnson/NNP said/VBD 0/-NONE- *T*-2/-NONE- ./.
Mr./NNP Lothson/NNP of/IN PaineWebber/NNP said/VBD 0/-NONE- the/DT company/NN 's/POS sales/NNS pace/NN has/VBZ been/VBN picking/VBG up/RP largely/RB because/IN the/DT effect/NN of/IN unfavorable/JJ exchange/NN rates/NNS has/VBZ been/VBN easing/VBG --/: a/DT pattern/NN continuing/VBG this/DT quarter/NN ./.
He/PRP cautioned/VBD ,/, however/RB ,/, that/IN a/DT ``/`` tough/JJ tax-rate/NN comparison/NN ''/'' may/MD slow/VB the/DT company/NN 's/POS earnings/NNS growth/NN for/IN the/DT current/JJ quarter/NN ./.
For/IN last/JJ year/NN 's/POS fourth/JJ quarter/NN ,/, the/DT company/NN 's/POS tax/NN rate/NN was/VBD less/JJR than/IN 20/CD %/NN ,/, he/PRP said/VBD 0/-NONE- *T*-1/-NONE- ./.
While/IN the/DT third/JJ period/NN contained/VBD no/DT major/JJ surprises/NNS ,/, Mr./NNP Lothson/NNP said/VBD 0/-NONE- *T*-2/-NONE- ,/, the/DT results/NNS show/VBP how/WRB sensitive/JJ the/DT multinationals/NNS can/MD be/VB *T*-1/-NONE- to/TO developments/NNS in/IN a/DT single/JJ country/NN such/JJ as/IN Brazil/NNP ./.
He/PRP also/RB questioned/VBD whether/IN recent/JJ gains/NNS in/IN that/DT country/NN can/MD be/VB sustained/VBN *-1/-NONE- ./.
The/DT following/JJ issues/NNS were/VBD recently/RB filed/VBN *-4/-NONE- with/IN the/DT Securities/NNP and/CC Exchange/NNP Commission/NNP :/:
Bergen/NNP Brunswig/NNP Corp./NNP ,/, proposed/JJ offering/NN of/IN liquid/JJ yield/NN option/NN notes/NNS ,/, via/IN Merrill/NNP Lynch/NNP Capital/NNP Markets/NNP ./.
Columbia/NNP Gas/NNP System/NNP Inc./NNP ,/, shelf/NN offering/NN of/IN up/IN to/TO $/$ 200/CD million/CD *U*/-NONE- of/IN debentures/NNS ./.
Laserscope/NNP ,/, initial/JJ offering/NN of/IN 1,656,870/CD common/JJ shares/NNS ,/, of/IN which/WDT 1,455,000/CD shares/NNS *T*-2/-NONE- are/VBP *-3/-NONE- to/TO be/VB sold/VBN *-1/-NONE- by/IN the/DT company/NN and/CC 201,870/CD *T*-2/-NONE- by/IN holders/NNS ,/, via/IN Alex/NNP ./. Brown/NNP &/CC Sons/NNP Inc./NNP and/CC Volpe/NNP ,/, Covington/NNP &/CC Welty/NNP ./.
TeleVideo/NNP Systems/NNP Inc./NNP ,/, proposed/JJ offering/NN of/IN 1,853,735/CD common/JJ shares/NNS ,/, 0/-NONE- *T*-1/-NONE- to/TO be/VB sold/VBN *-2/-NONE- by/IN holders/NNS ./.
Western/NNP Gas/NNP System/NNP Inc./NNP ,/, initial/JJ offering/NN of/IN 3,250,000/CD common/JJ shares/NNS ,/, of/IN which/WDT 3,040,000/CD shares/NNS *T*-1/-NONE- will/MD be/VB sold/VBN *-3/-NONE- by/IN the/DT company/NN and/CC 210,000/CD *T*-1/-NONE- by/IN a/DT holder/NN ,/, via/IN Prudential-Bache/NNP Capital/NNP Funding/NNP ,/, Smith/NNP Barney/NNP ,/, Harris/NNP Upham/NNP &/CC Co./NNP and/CC Hanifen/NNP ,/, Imhoff/NNP Inc/NNP ./.

